Factor II (Prothrombin) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Factor II (Prothrombin) Inhibitor The report ...
January 2022
60 pages
Factor IIa (Thrombin) Inhibitor - Pipeline Insight, 2022
US$ 2,000.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Factor IIa (Thrombin) Inhibitor The report assesses ...
January 2022
120 pages
Factor IX - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Factor IX The report assesses the active Factor IX pipeline ...
January 2022
60 pages
Factor IX A Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Factor IX A Inhibitor The report assesses ...
January 2022
60 pages
Factor VIIa Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Factor VIIa Inhibitor The report assesses the active Factor VIIa ...
January 2022
60 pages
Factor VIII Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... of Ablynx and SHP655 of Shire. Products covered by Phase Filed & Phase III Inactive (Dormant and Discontinued) Overview of pipeline development activities for Factor VIII Inhibitor Pipeline analysis of therapeutic drugs include but are ...
January 2022
60 pages
Farnesoid X Receptor (FXR) Agonist - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Farnesoid X Receptor (FXR) Agonist The report ...
January 2022
60 pages
Fatty Acid Amide Hydrolase (FAAH) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Fatty Acid Amide Hydrolase (FAAH) Inhibitor The report ...
January 2022
60 pages
Fatty Acid Synthase (FAS) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Fatty Acid Synthase (FAS) Inhibitor The report ...
January 2022
60 pages
Fc-Gamma Receptor Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Fc-Gamma Receptor Antagonist The report assesses ...
January 2022
60 pages
Fibroblast Activation Protein (FAP or Seprase) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Fibroblast Activation Protein (FAP or Seprase) Inhibitor The ...
January 2022
60 pages
Fibroblast Growth Factor (FGF) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Fibroblast Growth Factor (FGF) Inhibitor The report ...
January 2022
60 pages
Fibroblast Growth Factor 1 (FGF-1) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Fibroblast Growth Factor 1 (FGF-1) Inhibitor The report ...
January 2022
60 pages
Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitor The ...
January 2022
60 pages
Focal Adhesion Kinase (FAK) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Focal Adhesion Kinase (FAK) Inhibitor The report ...
January 2022
60 pages
Fusion Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Fusion Inhibitor The report assesses the active Fusion Inhibitor ...
January 2022
60 pages
G2 Checkpoint Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “G2 Checkpoint Inhibitor The report assesses ...
January 2022
60 pages
GABA Receptor Agonists - Pipeline Insight, 2022
US$ 2,000.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “GABA Receptor Agonist The report assesses the active GABA Receptor ...
January 2022
90 pages
GABA Receptor Modulators - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “GABA Receptor Modulators The report assesses ...
January 2022
60 pages
GABA Transaminase Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “GABA Transaminase Inhibitor The report assesses ...
January 2022
60 pages
GABAA Agonist - Pipeline Insight, 2022
US$ 2,000.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “GABAA Agonist The report assesses the active GABAA Agonist pipeline ...
January 2022
120 pages
GABAA Modulators - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “GABAA Modulators The report assesses the active GABAA Modulators ...
January 2022
60 pages
GABAB Agonist - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “GABAB Agonist The report assesses the active GABAB Agonist pipeline ...
January 2022
60 pages
Galectin Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Galectin Inhibitor ...
January 2022
60 pages
Gamma Secretase Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Gamma Secretase Inhibitor The report assesses ...
January 2022
60 pages
Ghrelin Receptor Agonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Ghrelin Receptor Agonist The report assesses ...
January 2022
60 pages
Glucagon Receptor Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Glucagon Receptor Antagonist The report assesses ...
January 2022
60 pages
Glucagon-Like Peptide (GLP) Agonist - Pipeline Insight, 2022
US$ 1,500.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Glucagon-Like Peptide (GLP) Agonist The report ...
January 2022
90 pages
Glucocorticoid induced tumor necrosis factor - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Glucocorticoid induced tumor necrosis factor The report ...
January 2022
60 pages
Glucocorticoid Receptor (GR) Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Glucocorticoid Receptor (GR) Antagonist The report ...
January 2022
60 pages
Glucokinase Activators - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Glucokinase Activators The report assesses the active Glucokinase ...
January 2022
60 pages
Glucosylceramide synthase inhibitors - Pipeline Insight, 2022
US$ 1,500.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Glucosylceramide Synthase Inhibitor The report ...
January 2022
60 pages
Glutamate Receptor Antagonists - Pipeline Insight, 2022
US$ 2,000.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Glutamate Receptor Antagonist The report assesses ...
January 2022
60 pages
Glycan Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Glycan Inhibitor The report assesses the active Glycan Inhibitor ...
January 2022
60 pages
Glycine Transporter Type-1 (Glyt-1) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Glycine Transporter Type-1 (Glyt-1) Inhibitor The ...
January 2022
60 pages
Glycogen Synthase Kinase 3 (GSK3) inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Glycogen Synthase Kinase 3 (GSK-3) Inhibitor The report ...
January 2022
60 pages
GM-CSF Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “GM-CSF Inhibitor The report assesses the active GM-CSF Inhibitor ...
January 2022
60 pages
G-Protein Coupled Receptor (GPCR) Agonist - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “G-Protein Coupled Receptor (GPCR) Agonist The report ...
January 2022
60 pages
Growth Hormone (GH) Agonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Growth Hormone (GH) Agonist The report assesses ...
January 2022
60 pages
Growth Hormone Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Growth Hormone Antagonist The report assesses ...
January 2022
60 pages
Guanylate Cyclase-Coupled Receptor Activators - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Guanylate Cyclase-Coupled Receptor Activators The ...
January 2022
60 pages
H Antagonist - Pipeline Insight, 2022
US$ 2,000.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “H Antagonist The report assesses the active H Antagonist pipeline ...
January 2022
120 pages
H 2 Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... 2 Antagonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent ...
January 2022
60 pages
H 3 Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... 3 Antagonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent ...
January 2022
60 pages
H 4 Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... 4 Antagonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent ...
January 2022
60 pages
Histone deacetylase (HDAC) Inhibitors- Pipeline Insight, 2022
US$ 2,500.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “HDAC Inhibitor The report assesses the active HDAC Inhibitor ...
January 2022
150 pages
Heat shock protein inhibitors - Pipeline Insight, 2022
US$ 1,500.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Heat Shock Protein (Hsp) Inhibitor The report ...
January 2022
60 pages
Hedgehog Signaling Pathway Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Hedgehog Signaling Pathway Antagonist The report ...
January 2022
60 pages
